Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Late Rejection of Renal Transplant”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Study completedNCT01873157
What this trial is testing

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

Who this might be right for
Late Rejection of Renal TransplantAntibody-mediated Rejection
Medical University of Vienna 44
Testing effectiveness (Phase 2)Study completedNCT03380377
What this trial is testing

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Who this might be right for
Antibody-mediated RejectionKidney Transplant; ComplicationsTransplant Glomerulopathy+3 more
Stanley Jordan, MD 10
Testing effectiveness (Phase 2)Study completedNCT03444103
What this trial is testing

A Pilot Trial of Clazakizumab in Late ABMR

Who this might be right for
Antibody-mediated Rejection
Medical University of Vienna 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04561986
What this trial is testing

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

Who this might be right for
Antibody-mediated Rejection
Vastra Gotaland Region 50
Testing effectiveness (Phase 2)Study completedNCT05021484
What this trial is testing

Felzartamab in Late Antibody-Mediated Rejection

Who this might be right for
Antibody-mediated Rejection
Farsad Eskandary 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT06503731
What this trial is testing

Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Who this might be right for
Antibody-mediated Rejection
argenx 33
Testing effectiveness (Phase 2)Looking for participantsNCT07219043
What this trial is testing

Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Who this might be right for
Microvascular Inflammation
Biogen 81
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07613359
What this trial is testing

Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

Who this might be right for
Antibody-Mediated Rejection (AMR)
Takeda 36
Large-scale testing (Phase 3)Active Not RecruitingNCT06685757
What this trial is testing

Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Who this might be right for
Antibody-mediated Rejection
Biogen 132
Post-approval studies (Phase 4)Looking for participantsNCT06676696
What this trial is testing

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

Who this might be right for
Renal Failure , ChronicGraft FailureGraft Rejection+2 more
Hospital Universitari Vall d'Hebron Research Institute 202
Not applicableLooking for participantsNCT07081126
What this trial is testing

Daratumumab for Late Antibody-Mediated Rejection

Who this might be right for
Kidney TansplantAcute Rejection (AR) of Transplanted Kidney
University Hospital, Martin 20